Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing
Antonio López-Beltrán(University of Córdoba), Markus Eckstein(Friedrich-Alexander-Universität Erlangen-Nürnberg), Sophie Wildsmith(AstraZeneca (United Kingdom)), Rodolfo Montironi(Marche Polytechnic University), Fernando López‐Ríos(Hospital Universitario 12 De Octubre)
Cited by 34
Related Papers
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
|Annals of Oncology|2020|365
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
|Cancers|2021|289